Endo International plc (OTC: ENDPQ), an American-Irish specialty pharmaceutical company, announced on Wednesday that its subsidiary Endo Ventures Limited has signed a contract with United States-based MAIA Pharmaceuticals, Inc. to distribute bivalirudin injection in a ready-to-use 250mg/50mL single-use vial in the United States.
Endo is to commercialise the FDA-approved product via its Par Sterile Products business and is expected to commence shipping this summer.
Scott Sims, SVP and General Manager, Injectable Solutions & Generics at Endo, said, 'Hospital providers have told us what they need--ready-to-use medications that allow them to focus on patients rather than preparation. Through this partnership with MAIA Pharmaceuticals, we are proud to answer that call with the only ready-to-use liquid format of bivalirudin.'
Carisma Therapeutics' CT-0525 IND application receives US FDA approval
Orexo's OX124 New Drug Application accepted for review by US Food and Drug Administration
GE HealthCare expands Critical Care Suite with FDA-cleared Pneumothorax detection algorithm
NanoVibronix initiates clinical study for UroShield at University of Michigan
Acrivon Therapeutics secures FDA Breakthrough Device designation for ACR-368 OncoSignature assay
Orexo's opioid overdose rescue medication, OX124, gains FDA acceptance for review
SpringWorks Therapeutics' Ogsiveo tablets receive US FDA approval
RedHill Biopharma granted five years' market exclusivity for Talicia by US FDA
Arcturus Therapeutics granted FDA Orphan Drug Designation for ARCT-032 to treat cystic fibrosis
Genelux secures FDA Fast Track designation for Olvi-Vec in ovarian cancer
EMA accepts Valneva's chikungunya vaccine application for accelerated assessment
Dupixent shows significant COPD exacerbation reduction in Phase 3 trial, accelerating FDA submission
Everest Medicines Nefecon receives Chinese regulatory approval